The stock of Sorrento Therapeutics, Inc. (SRNE) gained value after the company announced that a series of publications of Main Protease of Novel SARS-Cov-2 inhibitors which could be a potential treatment for the Covid-19 patients infected with SARS=CoV-2 variants of all concern including Omicron. Due to which the stock gained a value of more than 1.72% in the Pre-market to reach $5.03. At the end of the last trading session, the stock closed at $5.51. The average volume of the stock tared in the trading session was around 5.02 million.
Reason for the SRNE stock gain
As soon as the news of Sorrento Therapeutics hit the market the stock gained significantly and was trusted by the investors to invest in its stock forecasting its growth in the near future. The company announced in a series of publications that Main Protease of Novel SARS-Cov-2 inhibitors could be a potential treatment for the Covid-19 patients infected with SARS=CoV-2 variants of all concerns including Omicron.
Amongst the series one of the novel MPro inhibitors, MPI8, inhibits both MPro and cathepsin L, an important viral entry enzyme. This enzyme has high potency and selectivity. The different Analogs of the series have been evaluated by the company to form an oral anti-viral COVID drug for the treatment of patients that are infected with all the current or emerging variants of the SARS-Cov-2 which includes the deadly Omicron. In the series of different analogues a promising and potential candidate of unique features that are distinguished from SARS-CoV-2 MPro inhibitors published by others has been systematically evaluated and moved forward to the final stage of the pre-clinical phase.
Evidence in the experiments
The evidence shows in the experiments that the certain host proteases SARS-CoV-2 spike protein for viral packaging, interactions with ACE2, and viral entry into the host. It consists of 2 serine proteases one is furin and transmembrane protease serine 2 (TMPRSS2) and the other is cysteine protease cathepsin L. both the Small molecule medications that inhibit furin, transmembrane protease serine 2 (TMPRSS2), and cathepsin L have shown effective results in stopping the replication of SARS-CoV-2.
The Sorrento Therapeutics in partnership with Prof. Liu’s Lab at Texas A&M University is moving forward to evaluate the development of an oral anti-viral COVID drug.
Effects of the major development on its stock and conclusion
The investors seemed to take a high interest in SRNE stock. If the company succeeds to developed an anti-viral drug for Covid-19 and all of its current and emerging variants this will be a major breakthrough for it.
